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Abstract
Objective
The aim of this study was to evaluate the relevance of genetic variants of TLR5 (rs5744168) and TLR7 (rs179008) gene in 
systemic lupus erythematosus (SLE) in a Spanish population. 
Material and methods
Our study population consisted of 752 SLE patients and 1107 healthy controls. All individual were of Spanish Caucasian 
origin. The TLR5 and TLR7 polymorphisms were genotyped using a PCR system with pre-developed TaqMan allelic 
discrimination assay. 
Results
No statistically signiﬁcant differences were observed when the allele and genotype distribution of TLR5 rs5744168 and 
TLR7 rs179008 polymorphisms was compared between SLE patients and healthy controls. A signiﬁcant increase frequency 
in the CC genotype of the TLR5 rs5744168 polymorphism among SLE patients without nephritis was found (93% vs. 87% 
in SLE patients with nephritis, p=0.03, OR=2.11 95%CI 0.93-3.51). However, this difference did not reach statistical 
signiﬁcance in the allele frequencies (p=0.08).
Conclusion
These results suggest that the tested variations of TLR5 and TLR7 genes do not confer a relevant role in the susceptibility 
or severity to SLE in the Spanish population.
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Introduction
Systemic lupus erythematosus (SLE) 
is the prototypic systemic autoimmune 
disease and is characterized by B-cell 
hyperreactivity and the production of 
autoantibodies (1). Autoantibodies to 
DNA, RNA and associated proteins 
are common targets of the autoimmune 
response in SLE (2). The presence of 
these antinuclear antibodies has been 
detected in the serum of a majority of 
patients with SLE, and these antibodies 
result in the formation of immune com-
plexes (ICs) that deposit in tissues and 
induce inﬂammation, thereby contribut-
ing to disease pathology. In fact, DNA 
and/or RNA can behave as autoanti-
gens because they have the capacity 
to stimulate the innate immune system 
directly via Toll-like receptors (TLRs) 
or indirectly via Fcγ receptors (FcγR) 
and thereby promote the self-directed 
immune response, potentially leading 
to tolerance (3). The TLR family consti-
tutes an important group of pattern-rec-
ognition receptors that play an essential 
role in the activation and regulation of 
innate and adaptive immunity through 
the recognition of speciﬁc molecular 
patterns of pathogens (4, 5). Currently, 
11 TLR subtypes have been identiﬁed in 
humans, with each having speciﬁc lig-
ands, cellular localization and expres-
sion proﬁles. Stimulation of the TLR 
pathway culminates in NFκB activation 
and transcription of immune response 
genes, such as cytokines and chemok-
ines (5-7). Because of their central role 
in the regulation of inﬂammation and the 
immune response to pathogens, TLRs 
are excellent candidate genes in genetic 
susceptibility studies for autoimmune 
diseases, such as SLE. 
TLR5 gene is known to recognize the 
bacterial ﬂagellin and it located at 
1q41 (8), a chromosome region liked 
with susceptibility to SLE in different 
populations (9, 10). A stop codon poly-
morphism in the ligand-binding domain 
of TLR5 (TLR5 rs5744168 also called 
Arg392Stop or C1174T) is unable to 
mediate ﬂagellin signalling (11) and has 
been found associated with susceptibil-
ity to Legionnaires’ disease  (11), resist-
ance to Crohn’s disease (12) and SLE 
(13). These ﬁndings suggest that TLR5 
may be considered both a biological and 
a positional candidate gene for SLE. 
TLR7 has recently been described as 
a potential functional relevance gene 
in SLE (14). TLR7 is involved in the 
recognition of singled-stranded viral 
RNA (15). Recent studies in congenic 
mice bearing the Y-linked autoim-
mune accelerator (yaa) lupus suscep-
tibility locus, have showed that differ-
ences in expression of the TLR7 gene 
as well as environmental factors that 
induce TLR7 responses may result in 
increased B cell sensivity to RNA-con-
taining self-antigens (16, 17). In ad-
dition, TLR7 has the ability to induce 
the release of interferon-α (IFN-α), a 
cytokine that has been shown to have a 
relevant role in SLE (18). 
Due to the central role of these TLR 
(TLR5 and TLR7) genes within the in-
nate immune system, the aim of this 
study was to determine the role of 
genetic variations in these genes with 
SLE in a Spanish population.
Material and methods
Patients
Peripheral blood samples were ob-
tained after written informed consent 
from 752 SLE patients meeting the 
American College of Rheumatology 
criteria for SLE (19). These patients 
were recruited from nine Spanish hos-
pitals: Hospital Virgen de las Nieves 
and Hospital Clínico (Granada), Hos-
pital Virgen del Rocío (Seville), Hos-
pital Carlos-Haya and Hospital Vir-
gen de la Victoria (Málaga), Hospital 
Central (Oviedo), Hospital Parc Taullí 
(Sabadell), Hospital La Fe (Valen-
cia) and Hospital Xeral-Calde (Lugo). 
Similarly, blood was taken from 1107 
blood bank and bone marrow donors of 
the corresponding cities were included 
as healthy individuals. Both patient and 
control groups were of Spanish Cauca-
sian origin and were matched for age by 
mean age and sex by frequency match-
ing. Informed consent was provided by 
each individual included in the study. 
The samples were collected according 
to the Helsinki declaration. The study 
was approved by all local ethical com-
mittees from the corresponding cent-
ers. Demographic characteristics of the 
cases and controls in each population 
have been described previously (20).
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Genotyping of TLR5 and TLR7 
polymorphisms
DNA was obtained from peripheral 
blood, using QIAamp DNA Blood Maxi 
Kit (Qiagen, Hilden, Germany). TLR5 
and TLR7 genotyping were performed 
using a TaqMan SNP Genotyping As-
say (Applied Biosystems, Foster City, 
CA). The PCR reaction was carried out 
in a total reaction volume of 4 μl, con-
taing 50 ng genomic DNA as template, 
2 μl of Taqman genotyping master mix, 
0.1 μl of 20x assay mix and ddH2O up 
to 4 μl of ﬁnal volume. The ampliﬁca-
tion protocol used was: initial denatur-
ation at 95ºC for 10 min followed by 40 
cycles of denaturation at 92ºC for 15 s, 
and annealing / extension at 60ºC for 1 
min. After PCR, the genotype of each 
sample was automatically attributed by 
measuring the allele-speciﬁc ﬂuores-
cence in the ABI Prism 7900 Sequence 
Detection System, using the SDS 2.2.2 
software for allele discrimination (Ap-
plied Biosystems).
Statistic analysis
Allele and genotype frequencies were 
obtained by direct counting and for the 
statistical analysis to compare allelic 
and genotypic distributions we used 
the χ2 test. We assessed the quality of 
the genotype data by testing for Hardy-
Weinberg equilibrium in the case and 
control samples, using Fisher’s exact 
test (p>0.05). Odds ratio (OR) with 
95% conﬁdence intervals (95%CI) 
were calculated according to Woolf’s 
method. The software used was Stat-
Calc program (Epi Info 2002; Cent-
ers of Disease Control and Prevention, 
Atlanta, GA, USA). P-values below 
0.05 were regarded as statistically sig-
niﬁcant. The power of each study was 
computed as the probability of detect-
ing an association between TLR5 and 
TLR7 polymorphisms and SLE at the 
0.05 level of signiﬁcance, assuming an 
OR of 1.5 (small effect size).  Power 
analysis was estimated using the Quan-
to v 0.5 software (Department of Pre-
ventive Medicine University of South-
ern California, CA, USA).
Results
All the genotype frequencies in cases 
and healthy controls were not signiﬁ-
cantly different from those predicted 
by Hardy-Weinberg equilibrium. 
Table I shows the distribution of geno-
types and alleles of the TLR5 rs5744168 
polymorphism studied in SLE patients 
and controls. No statistically signiﬁ-
cant differences were observed when 
the allele and genotype distribution was 
compared between SLE patients and 
healthy controls. The allele frequencies 
found in our controls population are in 
good agreement with allele frequencies 
observed in other Caucasian popula-
tions (21). We next considered whether 
the TLR5 stop codon showed a prefer-
ential association with particular clini-
cal manifestations of SLE (Table II). A 
signiﬁcant increase frequency in the CC 
genotype among SLE patients without 
nephritis was found (93% vs. 87% in 
SLE patients with nephritis, p=0.03, 
OR=0.47 95%CI 0.28-1.07). However, 
this difference did not reach statistical 
signiﬁcance in the allele frequencies 
(p=0.08).
No TLR7 polymorphisms have been de-
scribed to date that inﬂuence the course 
of human diseases. Nevertheless, a re-
cent study detected a variants with a 
frequency over 5% (rs179008), which 
results in an aminoacid change from 
glutamine to leucine at codon 11 (Q11L) 
(22). We analyzed the TLR7 Q11L poly-
morphism in our cohort of SLE patients. 
No statistically signiﬁcant differences 
were observed between allele frequen-
cies of SLE patients and healthy con-
trols (Table III). In addition, we found 
Table I. Genetic and allelic distribution of TLR5 rs5744168 polymorphism in SLE patients 
and healthy controls.
TLR5 SLE patients Healthy controls p-value OR (95% CI)
rs5744168 n=752 (%) n=1107 (%) 
Genotypes     
CC 673 (89.5) 1009 (91.1) 0.2 0.83 (0.60-1.14)
CT 74 (9.8) 96 (8.7) 0.4 1.15 (0.83-1.60)
TT 5 (0.7) 2 (0.2) 0.1 3.70 (0.64-27.54)
Alleles 2n=1504  2n=2214  
C 1420 (94.4) 2114 (95.5) 0.1 0.80 (0.59-1.09)
T 84 (5.6) 100 (4.5) 0.1 1.25 (0.92-1.70)
Table II. Distribution of TLR5 rs5744168 genotypes (%) by clinical features of the SLE 
patients.
SLE feature  CC CT TT C T
Nephritis + 0.87* 0.13 0 0.93** 0.07
 – 0.93 0.6 0.08 0.97 0.03
Malar rash  + 0.93 0.07 0 96.4 3.6
 – 0.88 0.10 0.02 93.3 6.7
Discoide + 0.87 0.1 0.03 0.92 0.08
 – 0.91 0.08 0.01 0.095 0.05
Oral ulcer + 0.88 0.12 0 0.94 0.06
 – 0.93 0.06 0.01 0.96 0.04
Photosensivity + 0.92 0.08 0.01 0.96 0.04
 – 0.89 0.10 0.01 0.94 0.06
Arthritis + 0.92 0.09 0.01 0.95 0.05
 – 0.093 0.06 0.01 0.96 0.4
ANA + 0.91 0.08 0.01 0.95 0.5
 – 1.00 0 0 1.00 0
Anti-dsDNA Ab + 0.90 0.09 0.01 0.95 0.5
 – 0.96 0.03 0.01 0.97 0.03
*p=0.03, OR=0.47 95%CI 0.28-1.07.
**p=0.08.
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no association of this polymorphism 
and genotype frequencies in female pa-
tients with SLE (data not shown). We 
also estimated the allele frequencies in 
male with SLE and no deviation in the 
distribution compared with allele fre-
quencies in male controls was observed. 
In addition, available clinical features 
of patients with SLE were analyses for 
possible association with the different 
alleles or genotypes of TLR7 polymor-
phism. However, when we stratiﬁed 
SLE patients according to the presence 
of renal involvement, no statistically 
signiﬁcant differences were observed in 
the distribution of this polymorphism 
between SLE patients with or without 
lupus nephritis (data not shown). Simi-
larly, no signiﬁcant differences were 
observed between this genetic variant 
and the following variables, age at on-
set, articular involvement, cutaneous 
lesions, photosensivity, hematological 
alterations, neurological disorders and 
serositis (data not shown).
Discussion
Due to the central role of TLRs with-
in the innate immune system, genetic 
variation in this gene family may alter 
susceptibility to some diseases. Ge-
netic variations in the TLR genes have 
been associated with many inﬂamma-
tory and/or autoimmune diseases (13, 
23-26). Accumulating evidence indi-
cates a role of TLRs in the recognition 
of endogenous ligands which might be 
involved in these disorders (3, 27). 
In the present study we analysed a large 
cohort of SLE patients and healthy con-
trols to assess the role of TLR7 gene in 
the susceptibility to SLE, and tried to 
replicate the previously association re-
ported by Hawn et al. between the TLR5 
rs5744168 polymorphism and SLE 
(13). Our data revealed no evidence of 
association of these variants with SLE 
in a Caucasian cohort from Spain. These 
ﬁndings contradict a recent family based 
report, which found that TLR5 1174C 
allele confers protection from develop-
ing SLE (13). However, an in agreement 
with our data a study in two Caucasians 
populations from North-America could 
not replicate the initial association (21). 
Several reasons could be underlying 
this discrepancy. The ﬁrst result could 
emerge as a consequence of a type I er-
ror (false positive), as a result of exam-
ining the statistical power of the study 
using allelic OR results, and it conclud-
ed that it is underpowered to detect an 
association (<40%). On the contrary, the 
existence of a type II error (false nega-
tive) in our and Demirci et al. studies is 
unlikely because of the high statistical 
power of these studies (97% and 73%, 
respectively) to detect an effect similar 
to that observed in the ﬁrst study. 
Although TLR7 genetic variants are 
largely unexplored, Pisitkun et al. have 
reported that a genomic segmental du-
plication, which included the murine 
Tlr7 gene, and the translocation of this 
segment to the Yaa locus were associ-
ated with autoreactive B cell responses 
to RNA-related antigens. (16). How-
ever, the genomic increase in Tlr7 in a 
murine model of lupus cannot be trans-
lated directly to humans with SLE, 
since no signiﬁcant concordance be-
tween the relative number of gene cop-
ies and the SLE phenotype was found 
(28). Although these variants in the 
TLR7 seem not play a relevant role in 
human SLE, several evidences show a 
role of this gene in the development of 
the disease. Since TLR7 is located on 
chromosome X and there is an increase 
prevalence of SLE in women (29), it is 
suggested an X-linked genetic compo-
nent in SLE. In addition, IFN-α, a cy-
tokine critically involved in the patho-
genesis of SLE (18, 30), markedly 
increases B cell expression of TLR7 by 
plasmocytoid dendritic cells (31). 
In the present study we investigated 
for the ﬁrst time a TLR7 polymorphism 
(Q11L) to test SLE susceptibility, and 
we found no evidence of association. 
The possibility that this lack of associa-
tion could have arisen due to type II error 
seems unlikely, since we estimated that 
our cohort has enough power (>99%) to 
detect the effect of the polymorphism, 
taking into consideration an OR of 1.5 
at a 5% signiﬁcance level. Furthermore, 
allele frequencies in our control popula-
tion are similar to those reported in the 
SNP database (http://www.ncbi.nlm.
nih.gov/SNP/snp_ref.cgi?rs=179008) 
in other Caucasian-European popula-
tions. However, we cannot exclude the 
possibility that other polymorphisms of 
the TLR7 gene that are not in linkage 
disequilibrium with the alleles tested 
may contributed to the development of 
SLE. In addition, this SNP is located in 
a region of known copy number varia-
tion, which should be taken with caution 
in genotyping studies since the alleles 
may differ according to the number of 
copies carried. 
TLR5 and TLR7 signalling involves 
the adaptor protein myeloid differen-
tiation factor 88 (MyD88), since mice 
rendered MyD88-deﬁcient are unre-
sponsive to ligands for these TLRs (32) 
and that activation leads to the produc-
tion of proinﬂammatory cytokines such 
as TNF-α, IL6, IL1β and IL12. In ad-
dition, TLR stimulation generally leads 
to the production of IL12 and IL23 and 
thereby favours a Th1-type response 
(33). However, in previous studies, we 
failed to ﬁnd an association between 
genetic variants in these cytokines and 
other TLRs with SLE in our population 
(34-37).
In conclusion, although the clinical rel-
evance of TLR5 rs5744168 and TLR7 
rs179008 polymorphisms indicates the 
possible physiological effect of other 
polymorphisms in chronic inﬂammatory 
diseases, these variants seems not play a 
relevant role in SLE in our population. 
However, this ﬁnding cannot rule out a 
possible role of TLR5 and TLR7 in SLE 
pathogenesis therapeutic targets (38). 
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Table III. Allelic distribution of TLR7 rs179008 polymorphism in SLE patients and healthy 
controls.
TLR7 SLE patients Healthy controls  p-value OR (95% CI)
rs179008 n=752 (%) n=1107 (%)  
Alleles     
C 1104 (81.2) 1439 (80.6) 0.7 1.04 (0.87-1.23)
T 256 (18.8) 346 (19.4) 0.7 0.97 (0.80-1.54)
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